MARKET

KHTRF

KHTRF

Knight Therapeut
OTCPK
4.720
NaN%
Closed 09:30 03/13 EDT
OPEN
--
PREV CLOSE
4.720
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
4.720
52 WEEK LOW
3.840
MARKET CAP
466.01M
P/E (TTM)
-173.5294
1D
5D
1M
3M
1Y
5Y
1D
Notice of Knight Therapeutics' Fourth Quarter and Year End 2025 Results Conference Call
Barchart · 2d ago
Stocks in play: Knight Therapeutics Inc.
Barchart · 02/18 09:13
Knight Therapeutics Announces Regulatory Submission of NIKTIMVO® (Axatilimab) in Brazil
Barchart · 02/18 06:30
Analysts Are Bullish on These Healthcare Stocks: Knight Therapeutics (KHTRF), Roivant Sciences (ROIV)
TipRanks · 02/06 21:30
Knight Therapeutics announces Health Canada approval for WYNZORA
TipRanks · 12/18/2025 12:35
Stifel Nicolaus Keeps Their Buy Rating on Knight Therapeutics (KHTRF)
TipRanks · 11/11/2025 08:45
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 11/09/2025 16:10
Knight Therapeutics Reports Record Revenues Amid Challenges
TipRanks · 11/08/2025 00:38
More
About KHTRF
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company monitors investments in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by the Company such as Exelon and Impavido.

Webull offers Knight Therapeutics Inc stock information, including OTCPK: KHTRF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KHTRF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KHTRF stock methods without spending real money on the virtual paper trading platform.